Ecto-NTPDase-Inhibitors – Inhibitors for use in human therapy
The invention provides a new class of nucleosides
exhibiting a high affinity for individual ecto-nucleotidetriphosphate- diphosphohydrolases (E-NTPDases) which have been developed by researchers at the University of Bonn. The inhibitors are capable of inhibiting the metabolization of nucleotides by individual E-NTPDases and thus act as a highly selective indirect agonists of P2- receptors (ATP-, ADP-, UTP-, UDP-receptors). Therapeutic compounds which facilitate the signal transduction via P2-receptors can be used e.g. for the treatment of mucoviscidosis and cancer or for the modulation of inflammatory processes and the immune system. Furthermore, such compounds are valuable tools in biopharmaceutical research. The present invention thus comprises a novel class of therapeutically active compounds as well as methods for preparing the same.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All news from this category: Technology Offerings
Latest posts
Seawater as an electrical cable !?
Wireless power transfers in the ocean For drones that can be stationed underwater for the adoption of ICT in mariculture. Associate professor Masaya Tamura, Kousuke Murai (who has completed the…
Rare quadruple-helix DNA found in living human cells with glowing probes
New probes allow scientists to see four-stranded DNA interacting with molecules inside living human cells, unravelling its role in cellular processes. DNA usually forms the classic double helix shape of…
A rift in the retina may help repair the optic nerve
In experiments in mouse tissues and human cells, Johns Hopkins Medicine researchers say they have found that removing a membrane that lines the back of the eye may improve the…